About this visual
A dated snapshot of manufacturer self-pay programs, doses, and eligibility conditions.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.




💊 GLP-1 cash-pay pricing update — September 1, 2026
A few important pricing changes took effect today for patients paying out of pocket for obesity medications.
With commercial coverage becoming increasingly limited, manufacturer self-pay programs are playing a much bigger role in access.
What changed today?
🔹 Foundayo (orforglipron)
Lilly temporarily reduced two doses through 12/31/26:
• 0.8 mg — $149
• 2.5 mg — $149 ⬇️ from $199
• 5.5 mg — $199 ⬇️ from $299
• 9 mg — $299
• 14.5/17.2 mg — $299*
Patients can now move through the first three doses at $149 → $149 → $199.
🔹 Wegovy tablets
The temporary $149 promotional price for 4 mg ended 8/31:
• 1.5 mg — $149
• 4 mg — $199 ⬆️
• 9 mg — $299
• 25 mg — $299
Current injectable self-pay pricing:
🔹 Wegovy injection
• $199/month for the first 2 fills for eligible new patients†
• $349/month standard pricing
• Wegovy HD 7.2 mg — $399/month
🔹 Zepbound KwikPen (tirzepatide)
• 2.5 mg — $299
• 5 mg — $399
• 7.5–15 mg — $449*
At a glance:
Foundayo: $149–$299
Wegovy tablets: $149–$299
Wegovy injection: $349 standard
Wegovy HD: $399
Zepbound KwikPen: $299–$449
*Higher-dose Foundayo and Zepbound KwikPen pricing reflects purchase offers with refill-timing requirements.
†The $199 Wegovy offer is limited to the first two monthly fills for eligible new patients; standard pricing is $349/month.
Eligible Medicare Part D patients may separately qualify for the Medicare GLP-1 Bridge Program at $50/month.
Pricing current as of 9/1/26. Eligibility and program terms apply and may change.